Sartorius Stedim Biotech S.A.
SDMHFOTCHealthcare● Active
$206.01
$-4.99(-2.36%)
Market Cap$20.0B
P/E Ratio—
52W High$264.3
52W Low$178.3
Sartorius Stedim Biotech S.A. (SDMHF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SDMHF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 23, 2026EPS Actual
$1.35
Est. $1.40 · -3.6%
Revenue
$0.88B
Est. $0.88B · +0.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 23, 2026
After Market Close
▼ Miss EPS
SDMHF reports quarterly as a OTC-listed Medical - Instruments & Supplies company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 23, 2026 | $1.49 | — | — | — | $0.92B | — |
| ▼ Q2 FY2026 | Apr 23, 2026 | $1.40 | $1.35 | -3.6% | $0.88B | $0.88B | +0.3% |
| ▼ Q1 FY2026 | Feb 16, 2026 | $1.48 | $1.32 | -10.8% | $0.91B | $0.90B | +1.2% |
| ▼ Q4 FY2025 | Oct 16, 2025 | $1.15 | $0.91 | -21.1% | $0.97B | $0.90B | +7.8% |
| ▼ Q3 FY2025 | Jul 22, 2025 | $1.22 | $0.81 | -33.4% | $0.88B | $0.85B | +3.3% |
| ▼ Q2 FY2025 | Apr 16, 2025 | $1.02 | $0.96 | -5.4% | $0.82B | $0.83B | -1.3% |
| ▼ Q1 FY2025 | Jan 28, 2025 | $0.98 | $0.49 | -50.3% | $0.78B | $0.74B | +5.2% |
| ▼ Q4 FY2024 | Oct 17, 2024 | $0.89 | $0.29 | -67.6% | $0.72B | $0.77B | -7.3% |
Q3 FY2026
Jul 23, 2026
EPS Actual
—
EPS Est.
$1.49
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 23, 2026Miss
EPS Actual
$1.35
EPS Est.
$1.40
EPS Surpr.
-3.6%
Revenue
$0.88B
Q1 FY2026
Feb 16, 2026Miss
EPS Actual
$1.32
EPS Est.
$1.48
EPS Surpr.
-10.8%
Revenue
$0.91B
Q4 FY2025
Oct 16, 2025Miss
EPS Actual
$0.91
EPS Est.
$1.15
EPS Surpr.
-21.1%
Revenue
$0.97B
Q3 FY2025
Jul 22, 2025Miss
EPS Actual
$0.81
EPS Est.
$1.22
EPS Surpr.
-33.4%
Revenue
$0.88B
Q2 FY2025
Apr 16, 2025Miss
EPS Actual
$0.96
EPS Est.
$1.02
EPS Surpr.
-5.4%
Revenue
$0.82B
Q1 FY2025
Jan 28, 2025Miss
EPS Actual
$0.49
EPS Est.
$0.98
EPS Surpr.
-50.3%
Revenue
$0.78B
Q4 FY2024
Oct 17, 2024Miss
EPS Actual
$0.29
EPS Est.
$0.89
EPS Surpr.
-67.6%
Revenue
$0.72B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $1.53 | $1.54 | $1.56 | 1 |
| Q3 FY2026 | $1.24 | $1.25 | $1.26 | 1 |
| Q2 FY2026 | $1.30 | $1.31 | $1.32 | 1 |
| Q1 FY2026 | $1.21 | $1.22 | $1.23 | 1 |
| Q4 FY2025 | $1.25 | $1.26 | $1.28 | 1 |
| Q3 FY2025 | $0.98 | $0.98 | $0.99 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.9B | $0.9B | $0.9B | 2 |
| Q3 FY2026 | $0.8B | $0.8B | $0.8B | 3 |
| Q2 FY2026 | $0.8B | $0.8B | $0.8B | 3 |
| Q1 FY2026 | $0.8B | $0.8B | $0.8B | 5 |
| Q4 FY2025 | $0.8B | $0.8B | $0.8B | 5 |
| Q3 FY2025 | $0.7B | $0.7B | $0.7B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 23, 2026 | -3.6% | $224.50 | $187.00 | -16.70% |
| ▼ Q1 FY2026 | Feb 16, 2026 | -10.8% | $207.00 | $207.00 | +0.00% |
| ▼ Q4 FY2025 | Oct 16, 2025 | -21.1% | $219.50 | $219.50 | +0.00% |
| ▼ Q3 FY2025 | Jul 22, 2025 | -33.4% | $244.35 | $206.95 | -15.31% |
| ▼ Q2 FY2025 | Apr 16, 2025 | -5.4% | $195.68 | $214.00 | +9.36% |
| ▼ Q1 FY2025 | Jan 28, 2025 | -50.3% | $213.10 | $213.10 | +0.00% |
| ▼ Q4 FY2024 | Oct 17, 2024 | -67.6% | $201.75 | $221.50 | +9.79% |
| ▼ Q3 FY2024 | Jul 18, 2024 | -50.8% | $176.20 | $190.00 | +7.83% |
Q2 FY2026-16.70%
Report Date
Apr 23, 2026
EPS Beat/Miss
-3.6%
Price Before
$224.50
Price After
$187.00
Q1 FY2026+0.00%
Report Date
Feb 16, 2026
EPS Beat/Miss
-10.8%
Price Before
$207.00
Price After
$207.00
Q4 FY2025+0.00%
Report Date
Oct 16, 2025
EPS Beat/Miss
-21.1%
Price Before
$219.50
Price After
$219.50
Q3 FY2025-15.31%
Report Date
Jul 22, 2025
EPS Beat/Miss
-33.4%
Price Before
$244.35
Price After
$206.95
Q2 FY2025+9.36%
Report Date
Apr 16, 2025
EPS Beat/Miss
-5.4%
Price Before
$195.68
Price After
$214.00
Q1 FY2025+0.00%
Report Date
Jan 28, 2025
EPS Beat/Miss
-50.3%
Price Before
$213.10
Price After
$213.10
Q4 FY2024+9.79%
Report Date
Oct 17, 2024
EPS Beat/Miss
-67.6%
Price Before
$201.75
Price After
$221.50
Q3 FY2024+7.83%
Report Date
Jul 18, 2024
EPS Beat/Miss
-50.8%
Price Before
$176.20
Price After
$190.00
Avg Miss Reaction-0.63%
Beat Rate0 / 8 quarters
Largest Move-16.70% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SDMHF ends December
Sartorius Stedim Biotech S.A. (SDMHF) most recently reported earnings on April 23, 2026 for Q2 FY2026, posting EPS of $1.35 — missing the analyst consensus of $1.40 by -3.6%. The next SDMHF earnings date is expected around September 1, 2026.
Each quarter, investors track SDMHF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SDMHF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SDMHF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SDMHF earnings · 5 questionsSartorius Stedim Biotech S.A.'s next earnings report is expected around September 1, 2026. SDMHF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SDMHF historically reports after market close (AMC).
SDMHF earnings datewhen is SDMHF earningsSDMHF next earnings datewhen does SDMHF report earningsSDMHF earnings calendar
▸ Source: FMP · Sartorius Stedim Biotech S.A. SEC filings · US GAAP · Sartorius Stedim Biotech S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026